Content about Pharmaceutical sciences

January 31, 2014

Actavis on Friday announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth.

DUBLIN — Actavis on Friday announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth. 

January 31, 2014

Following the announcement that Rep. Henry Waxman, D-Calif., intended to retire, the Generic Pharmaceutical Association bid adieu to a legislator who had a tremendous positive impact on the generic industry.

WASHINGTON — Following the announcement that Rep. Henry Waxman, D-Calif., intended to retire, the Generic Pharmaceutical Association on Thursday bid adieu to a legislator who had a tremendous positive impact on the generic industry. 

January 31, 2014

The Biotechnology Industry Organization and the Indiana Health Industry Forum commended the Indiana Senate for passing legislation designed to create a pathway for the substitution of interchangeable biologic medicines.

WASHINGTON — The Biotechnology Industry Organization and the Indiana Health Industry Forum on Thursday commended the Indiana Senate for passing legislation designed to create a pathway for the substitution of interchangeable biologic medicines.

The policies outlined in the identical SB 262 align with BIO’s principles on biologic substitution, therefore BIO and IHIF support passage of this bill as it moves along for consideration by the Indiana House of Representatives.

January 30, 2014

Novartis Consumer Health will be relaunching Theraflu for the 2014-2015 cough-cold season, Brian McNamara, Novartis division head OTC, told analysts.

BASEL, Switzerland — Novartis Consumer Health will be relaunching Theraflu for the 2014-2015 cough-cold season, Brian McNamara, Novartis division head OTC, told analysts Wednesday. 

"As you know, in the U.S. business we launched Lamisil and Triaminic and Excedrin end of 2012 and 2013. About halfway through the year, we launched Benefiber. And for next year, we expect to launch Theraflu for that cough and cold season," he said. 

January 30, 2014

Rite Aid's January same-store sales increased 1.8%, beating out an analyst projection of a 0.5% increase in overall comparable-store sales. Total drug store sales for the four weeks ended Jan. 25 increased 1.5% to $1.9 billion.

CAMP HILL, Pa. — Rite Aid's January same-store sales increased 1.8%, beating out an analyst projection of a 0.5% increase in overall comparable-store sales. Total drug store sales for the four weeks ended Jan. 25 increased 1.5% to $1.9 billion.

January front-end same-store sales decreased 1.3%, of which 1.4% was attributable to a decrease in sales of flu-related over-the-counter products. Pharmacy same-store sales, which included an approximate 124 basis points negative impact from new generic introductions, increased 3.2%. 

January 29, 2014

Ateb recently named Rebecca Chater as its executive healthcare strategist and added Bjorn Thommesen to the team.

RALEIGH, N.C. — Ateb recently named Rebecca Chater as its executive healthcare strategist and added Bjorn Thommesen to the team.

Chater will provide clinical leadership of Ateb’s patient care support solutions and thought leadership to influence broad integration of pharmacy and pharmacist services among healthcare stakeholders to improve patient care coordination and health outcomes.

January 29, 2014

A pair of Food and Drug Administration advisory committees will be meeting Feb. 10 to talk about heart risks associated with use of NSAIDs and whether or not Bayer's Aleve (naproxen) carries a lower risk profile than other NSAIDs

SILVER SPRING, Md. — A pair of Food and Drug Administration advisory committees will be meeting Feb. 10 to talk about heart risks associated with use of NSAIDs and whether or not Bayer's Aleve (naproxen) carries a lower risk profile than other NSAIDs. The FDA is also considering potentially revoking OTC status of certain nonprescription NSAIDS, according to published reports

January 29, 2014

Almost two-thirds of specialty pharmacy revenues are attributed to 1-of-3 companies, and the specialty pharmacy market is poised to explode, according to a Drug Channels Institute report.

PHILADELPHIA — Almost two-thirds of specialty pharmacy revenues are attributed to 1-of-3 companies, and the specialty pharmacy market is poised to explode, according to a Drug Channels Institute report released Tuesday. 

January 28, 2014

In 2012, compounding made headlines when 64 people died as a result of fungal meningitis caused by contaminated compounded products.

In 2012, compounding made headlines when 64 people died as a result of fungal meningitis caused by contaminated compounded products.

History

January 28, 2014

The Generic Pharmaceutical Association on Tuesday announced the hiring of Jonathan Marks as VP international affairs.

WASHINGTON — The Generic Pharmaceutical Association on Tuesday announced the hiring of Jonathan Marks as VP international affairs. Marks brings to GPhA more than 20 years of experience, including previous roles within the Department of Commerce. 

January 28, 2014

Roxane Labs announced the launch of telmisartan tablets USP, an authorized generic version of Boehringer Ingelheim's Micardis tablets.

COLUMBUS, OH — Roxane Labs announced the launch of telmisartan tablets USP. The product is available in unit dose packages of 30 tablets.

Roxane Labs' telmisartan is the authorized generic of Micardis tablets from Boehringer Ingelheim. The product, which used to treat high blood pressure, is available for immediate shipment to wholesalers and pharmacies nationwide.

 

January 27, 2014

Purdue Pharma on Monday named Mark Timney as president and CEO. Timney succeeds John Stewart, who has retired from Purdue.

STAMFORD, Conn. — Purdue Pharma on Monday named Mark Timney as president and CEO.

"We found a proven leader in Mark Timney," said Raymond Sackler, co-founder and board member of Purdue. "I am confident that his capabilities and experience, coupled with Purdue's culture of excellence, will grow our business and strengthen our healthcare industry leadership." 

January 24, 2014

Hi-Tech Pharmacal Co., a specialty pharmaceuticals company, announced that it was granted final approval from the Food and Drug Administration for bromfenac ophthalmic solution 0.09% (once-a-day).

AMITYVILLE, N.Y. — Hi-Tech Pharmacal Co., a specialty pharmaceuticals company, on Thursday announced that it was granted final approval from the Food and Drug Administration for bromfenac ophthalmic solution 0.09% (once-a-day), a generic version of ISTA Pharmaceuticals’ Bromday ophthalmic solution, 0.09%.

The product is used to treat post-op inflammation and reduction of ocular pain in patients who have had cataract surgery. The company plans to launch the product immediately.

January 24, 2014

Legislative relief that would result in a more balanced business relationship between Ohio community pharmacists and PBMs is critical, according to the National Community Pharmacists Association.

ALEXANDRIA, Va. — Legislative relief that would result in a more balanced business relationship between Ohio community pharmacists and PBMs is critical, according to the National Community Pharmacists Association.

January 24, 2014

Perrigo announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets.

DUBLIN — Perrigo Co. announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets — in 1-mg and 2-mg strengths. The company has started shipment of the drug. Perrigo previously launched the 0.5-mg strength in 2013.

January 22, 2014

According to an economic impact analysis released Tuesday by Martin Kennedy, a former professor of economics who spent seven years on the faculty of Middle Tennessee State University, adopting a prescription requirement for pseudoephedrine products in Tennessee would result in an influx of more than 497,000 additional physician office visits at a direct cost of $44.3 million annually.

WASHINGTON — According to an economic impact analysis released Tuesday by Martin Kennedy, a former professor of economics who spent seven years on the faculty of Middle Tennessee State University, adopting a prescription requirement for pseudoephedrine products in Tennessee would result in an influx of more than 497,000 additional physician office visits at a direct cost of $44.3 million annually.

January 22, 2014

The Food and Drug Administration launched the advisory committee membership nomination portal, an online, interactive system that allows interested individuals to submit nominations for membership to any of the agency’s 33 advisory committees.

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday launched the advisory committee membership nomination portal, an online, interactive system that allows interested individuals to submit nominations for membership to any of the agency’s 33 advisory committees.  

January 21, 2014

Mobile. It is changing the way in which customers manage their drug store needs whether it be filling a prescription, accessing health resources or buying products, and CVS/pharmacy is aiming to take the lead in today’s digital space with a slew of innovative offerings that are yielding some significant results.

WOONSOCKET, R.I. — Mobile. It is changing the way in which customers manage their drug store needs whether it be filling a prescription, accessing health resources or buying products, and CVS/pharmacy is aiming to take the lead in today’s digital space with a slew of innovative offerings that are yielding some significant results.

January 21, 2014

With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report by the IMS Institute for Healthcare Informatics.

PARSIPPANY, N.J. — With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report released Tuesday by the IMS Institute for Healthcare Informatics. 

January 21, 2014

The Consumer Healthcare Products Association responded to Sen. Charles Schumer’s, D-N.Y., recent call for the Food and Drug Administration and the Consumer Product Safety Commission to require flow restrictors on all bottles of children's liquid medicines.

WASHINGTON — The Consumer Healthcare Products Association on Monday responded to Sen. Charles Schumer’s, D-N.Y., recent call for the Food and Drug Administration and the Consumer Product Safety Commission to require flow restrictors on all bottles of children's liquid medicines.

January 20, 2014

Publix Super Markets is rolling out their Time My Meds powered medication synchronization program, Sync Your Refills, to all of its pharmacy locations.

RALEIGH, N.C. — Publix Super Markets is rolling out their Time My Meds powered medication synchronization program, Sync Your Refills, to all of its pharmacy locations. 

January 17, 2014

The Consumer Healthcare Products Association responded to the Food and Drug Administration’s recommendation to discontinue prescribing and dispensing prescription combination medicines that contain more than 325 mg of acetaminophen per dosage unit, suggesting it would not impact use of over-the-counter formulations containing acetaminophen.

WASHINGTON — The Consumer Healthcare Products Association on Thursday responded to the Food and Drug Administration’s recommendation to discontinue prescribing and dispensing prescription combination medicines that contain more than 325 mg of acetaminophen per dosage unit, suggesting it would not impact use of over-the-counter formulations containing acetaminophen.

January 17, 2014

The Medicare Part D program and taxpayers often pay more when prescription drugs are obtained through "preferred" pharmacies and mail order than they would if the same prescriptions were filled through other, "non-preferred" pharmacies, according to a cost comparison made by the National Community Pharmacists Association released Thursday using the Medicare Plan Finder website.

ALEXANDRIA, Va. — The Medicare Part D program and taxpayers often pay more when prescription drugs are obtained through "preferred" pharmacies and mail order than they would if the same prescriptions were filled through other, "non-preferred" pharmacies, according to a cost comparison made by the National Community Pharmacists Association released Thursday using the Medicare Plan Finder website. The findings come shortly after recently proposed requirements that officials with the U.S.

January 16, 2014

Easton Pharmaceuticals on Thursday announced it is speeding up negotiations with an Ontario-based company toward forming a possible investment/partnership toward their medical marijuana initiatives, which includes participating in their government application for both a growers and distributorship license in Canada and other possible international initiatives.

TORONTO — Easton Pharmaceuticals on Thursday announced it is speeding up negotiations with an Ontario-based company toward forming a possible investment/partnership toward their medical marijuana initiatives, which includes participating in their government application for both a growers and distributorship license in Canada and other possible international initiatives. 

January 16, 2014

Merck on Wednesday commended the U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee’s recommendation for approval of vorapaxar.

WHITEHOUSE STATION, N.J. — Merck on Wednesday commended the U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee’s recommendation for approval of vorapaxar. Vorapaxar is the company’s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack.